Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.43 |
| ▸ | GRM5 | P41594 | 4/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | ITGAL | P20701 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15474174 | 0.81 | PIK3CA (0.43) | MMEPIK3CAGRM5PDCD1CD274 | |
| SCHEMBL9966275 | 0.78 | MME (0.41) | MMEPIK3CAGRM5PDCD1CD274 | |
| SCHEMBL9963904 | 0.78 | MME (0.39) | MMEPIK3CAGRM5PDCD1CD274 | |
| SCHEMBL9974749 | 0.76 | PIK3CA (0.39) | MMEPIK3CAGRM5NOTUMPIK3CD | |
| SCHEMBL21650118 | 0.70 | PIK3CA (0.37) | MMEPIK3CAGRM5NOTUMPIK3CD | |
| SCHEMBL14979000 | 0.70 | KDM4E (0.38) | MMEPIK3CAMAPTNOTUMPIK3CB | |
| SCHEMBL9963883 | 0.67 | ADORA3 (0.35) | MMEPIK3CAGRM5NOTUMPIK3CB | |
| SCHEMBL9966172 | 0.67 | GRM5 (0.39) | MMEPIK3CAGRM5THRBNOTUM | |
| SCHEMBL14212421 | 0.65 | ITGB2 (0.39) | PIK3CANOTUMITGB2ICAM1ITGAL | |
| SCHEMBL30122993 | 0.65 | ITGB2 (0.39) | PIK3CANOTUMITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210079017-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-18 | — | — | US | disclosed |
| US-10759813-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200031847-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-01-30 | — | — | US | disclosed |
| US-9688692-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170022219-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-26 | — | — | US | disclosed |
| WO-2012082853-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759813-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885PIK3CA 3962/4885GRM5 3026/4885 |
| US-20170022219-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885PIK3CA 3962/4885GRM5 3026/4885 |
| US-20210079017-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885PIK3CA 3962/4885GRM5 3026/4885 |
| US-20200031847-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885PIK3CA 3962/4885GRM5 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.